Position in ACAD
as of Mar 31, 2026
· filed Apr 20, 2026
Position Value
$11,130
-$2,225 QoQ
Shares Held
500
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ACAD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026BROWN, LISLE/CUMMINGS, INC. holds $256,199 across 16 Biotechnology names. ACAD ranks #7 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
82 | $63,356 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
162 | $53,600 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
115 | $51,352 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
377 | $24,365 | |
| 5 | MRNA |
Moderna, Inc.
|
375 | $19,050 | |
| 6 | VKTX |
Viking Therapeutics, Inc.
|
400 | $13,016 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
This page
|
500 | $11,130 | |
| 8 | RPRX |
Royalty Pharma plc
|
217 | $10,409 |
All Filings in ACAD
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,130 | 500 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $13,355 | 500 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $10,670 | 500 | Shares | Sole | 2025-10-10 | |
| 2025-06-30 | $10,785 | 500 | Shares | Sole | 2025-07-16 | |
| 2025-03-31 | $8,305 | 500 | Shares | Sole | 2025-04-22 | |
| 2024-12-31 | $9,175 | 500 | Shares | Sole | 2025-01-27 | |
| 2024-09-30 | $3,845 | 250 | Shares | Sole | 2024-10-18 | |
| 2024-06-30 | $4,062 | 250 | Shares | Sole | 2024-07-17 | |
| No filing history on record for this holder in this stock. | ||||||